These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Is the use of t-PA as compared with streptokinase cost effective? Rose EA N Engl J Med; 1995 Oct; 333(15):1009; author reply 1010. PubMed ID: 7666904 [No Abstract] [Full Text] [Related]
7. Is the use of t-PA as compared with streptokinase cost effective? Armentano R; Favaloro RG N Engl J Med; 1995 Oct; 333(15):1009-10. PubMed ID: 7666905 [No Abstract] [Full Text] [Related]
8. Primary PTCA versus thrombolysis with tPA in acute myocardial infarction: a formal cost-effectiveness analysis. Müllner M; Paulis M; Nikfardjam M; Domanovits H; Huber K Wien Klin Wochenschr; 1999 Jan; 111(1):37-41. PubMed ID: 10067269 [TBL] [Abstract][Full Text] [Related]
9. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective]. Lorenzoni R; Fattore G; Gensini G G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862 [TBL] [Abstract][Full Text] [Related]
10. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction. Goel V; Naylor CD Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509 [TBL] [Abstract][Full Text] [Related]
11. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Coyle D; Buxton MJ; O'Brien BJ Health Econ; 2003 May; 12(5):421-7. PubMed ID: 12720259 [TBL] [Abstract][Full Text] [Related]
12. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy. Lessler DS; Avins AL Arch Intern Med; 1992 Aug; 152(8):1665-72. PubMed ID: 1497400 [TBL] [Abstract][Full Text] [Related]
14. [An economic evaluation of low dose recombinant human tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism]. Wu YQ; Tao LB; Lü C; Hu YH Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(2):103-6. PubMed ID: 20356492 [TBL] [Abstract][Full Text] [Related]
15. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. Califf RM; Stump D; Topol EJ; Mark DB Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606 [No Abstract] [Full Text] [Related]
20. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs. Tsui W; Pierre K; Massel D Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]